Header image

Session 12C: The new front line: Biotechnology as strategic infrastructure

Tracks
Track 3
Friday, October 23, 2026
2:55 PM - 3:40 PM
Discovery & Advanced Therapeutics Breakout Room

Details

The global race for biotechnology has entered a new phase. Around the world, governments are investing in biotechnology not only to improve healthcare, but to strengthen national resilience, economic security and geopolitical competitiveness. From biosecurity and advanced manufacturing to sovereign capability and trusted supply chains, biotechnology is increasingly recognised as strategic infrastructure. As new partnerships emerge between industry, government and defence, this leadership discussion explores how these investments are reshaping innovation, creating new funding and commercialisation pathways, and positioning Australia to become a trusted global partner in the next generation of strategic biotechnology.


Speaker

Agenda Item Image
Dr Stuart Newman
CEO
Therapeutic Innovation Australia

Panellist

Agenda Item Image
Dr. Emma Prato
Program Lead - Medical Countermeasures
DMTC Limited

Chair

Mr Mark Reid
Managing Director
Graythan Regulatory Services

Panellist

Agenda Item Image
Dr. Christopher Steele
Chief of Strategy & Business Development
Medical Technology Enterprise Consortium

Panellist

Agenda Item Image
Dr. Kirsten Weand
Chief Science and Technology Officer, Vigilance
Alloy Therapeutics

Panellist

loading